4. Psoriasis and Other Dermatoses

Learning Objectives

• Explain the immune-mediated pathogenesis of psoriasis, including the IL-23/Th17 axis and accelerated keratinocyte turnover
• Recognize and differentiate the five clinical subtypes of psoriasis by morphology and distribution
• Describe the Koebner phenomenon and identify common triggers for psoriasis flares
• Apply the topical, phototherapy, systemic, and biologic treatment ladder to disease severity
• Identify psoriatic arthritis and other comorbidities associated with psoriasis
• Distinguish psoriasis from clinically similar dermatoses using key differentiating features

Quick Answer

Psoriasis is a chronic, immune-mediated skin disease in which T-cell driven inflammation causes keratinocytes to turn over roughly ten times faster than normal (about every 3–4 days instead of 28), producing thick, well-demarcated, silvery-scaled plaques. It affects roughly 2–3% of the global population and is not simply a skin problem — up to 30% of patients develop psoriatic arthritis, and psoriasis carries increased cardiovascular and metabolic risk. It matters clinically because it is a systemic inflammatory disease that happens to be visible on the skin, and because the last two decades of biologic therapy (targeting TNF-alpha, IL-17, and IL-23) have transformed outcomes for moderate-to-severe disease.

This page is for educational purposes. Always verify with current clinical guidelines.

Overview

Psoriasis used to be taught as a keratinocyte disease — as if the skin cells themselves were simply misbehaving. That framing is outdated. Psoriasis is now understood as a T-cell mediated autoimmune disease in which the immune system mistakenly drives inflammatory signaling in the skin, and the thickened, scaly plaques are the downstream result of that inflammation, not its cause. This distinction matters because it explains why psoriasis responds to immune-targeted biologics rather than just moisturizers, and why it clusters with other immune-mediated conditions like inflammatory bowel disease and psoriatic arthritis.

Genetics load the gun (HLA-Cw6 is the strongest known risk allele) and environmental triggers — streptococcal infection, skin trauma, stress, certain drugs — pull the trigger. Once triggered, a feedback loop between dendritic cells, T-cells, and keratinocytes becomes self-sustaining, which is why psoriasis is a lifelong relapsing-remitting condition rather than something that resolves on its own.

Pathogenesis: The IL-23/Th17 Axis

The modern model of psoriasis centers on a specific immune circuit rather than a vague "immune dysregulation."

This is why the modern biologic drug classes are named after exactly the cytokines in this pathway — ustekinumab blocks the shared p40 subunit of IL-12/IL-23, guselkumab and risankizumab block IL-23 specifically, and secukinumab and ixekizumab block IL-17. Understanding the diagram above is the fastest way to remember which drug targets which cytokine.

Definition

Psoriasis pathogenesis is the self-amplifying interaction between innate immune activation (dendritic cells and cytokines) and adaptive immune activation (Th17 cells), which together drive keratinocytes to proliferate far faster than normal.

Explanation

Normally, a keratinocyte is born in the basal layer, migrates upward, and is shed as dead stratum corneum after about 28 days — enough time to fully mature, lose its nucleus, and form an effective barrier. In psoriasis, IL-17 and IL-22 from Th17 cells push that entire cycle down to 3–4 days. Keratinocytes reach the surface still nucleated (parakeratosis) and without a properly formed barrier, so the scale is thick, silvery, and flakes easily, and the epidermis as a whole is markedly thickened (acanthosis).

Example

A patient scratches an area of normal-appearing skin on the forearm. Ten to fourteen days later, a new psoriatic plaque appears exactly along the scratch line. This is the Koebner phenomenon — trauma to the skin triggering new lesions at the site of injury — and it is a direct clinical demonstration that inflammation, not the pre-existing plaque, is what generates new lesions.

Real-World Example

A patient with chronic plaque psoriasis develops a streptococcal throat infection. Two to three weeks later they break out in dozens of small, drop-like (guttate) lesions across the trunk. This reflects molecular mimicry — streptococcal M-protein shares structural similarity with keratin, and the resulting immune response cross-reacts with skin.

Why It Matters

Because the disease is immune-driven rather than purely a "skin cell problem," topical treatment alone is often insufficient for moderate-to-severe disease — the inflammatory drive has to be addressed systemically, which is the entire rationale behind biologic therapy.

Common Misunderstanding

Students often assume psoriasis plaques are simply "extra skin cells piling up," similar to a callus. In reality, the plaque is an active inflammatory lesion with dilated, tortuous dermal blood vessels just beneath a thin epidermis over the rete ridges — which is exactly why removing the scale produces pinpoint bleeding (Auspitz sign), a finding that would never occur with a mechanical callus.

Clinical Subtypes

Psoriasis is not one disease morphologically — recognizing the subtype changes both the differential diagnosis and the urgency of treatment.

Subtype	Morphology	Typical Distribution	Key Trigger/Association
Plaque (psoriasis vulgaris)	Well-demarcated, raised, erythematous plaques with silvery scale	Extensor surfaces: elbows, knees, scalp, lumbosacral back	Most common (~80–90% of cases); chronic, relapsing
Guttate	Small (<1 cm), drop-shaped, salmon-pink papules with fine scale	Trunk and proximal extremities	Streptococcal pharyngitis, often in children/young adults
Inverse (flexural)	Smooth, shiny, erythematous plaques, minimal scale (macerated by moisture)	Axillae, groin, inframammary folds, gluteal cleft	Friction and moisture; often misdiagnosed as fungal infection
Pustular	Sterile, coalescing pustules on erythematous base	Generalized (von Zumbusch) or palms/soles	Can be triggered by rapid corticosteroid withdrawal — a dermatologic emergency when generalized
Erythrodermic	Widespread erythema and scaling over >75–90% of body surface	Diffuse, whole-body	Medical emergency: risk of fluid/electrolyte loss, hypothermia, high-output cardiac failure

Definition

A "subtype" of psoriasis refers to a distinct morphologic and clinical presentation of the same underlying IL-23/Th17-driven disease process.

Explanation

The same pathogenic pathway can manifest differently depending on the rate of keratinocyte turnover, the degree of pustule formation (neutrophil-predominant vs. lymphocyte-predominant inflammation), and the anatomic site (flexural sites lack the thick stratum corneum of extensor surfaces, so plaques there look smooth rather than scaly).

Example

A 12-year-old with no personal history of psoriasis develops a sudden shower of small pink, scaly papules on the trunk two weeks after a sore throat — classic guttate psoriasis, which frequently resolves on its own but can evolve into chronic plaque disease.

Real-World Example

An obese adult with erythematous, macerated, non-scaly patches in the groin is initially treated for candidal intertrigo with antifungals and fails to improve — the actual diagnosis is inverse psoriasis, which lacks the classic scale because moisture in flexural folds keeps the plaques thin and shiny.

Why It Matters

Generalized pustular psoriasis and erythrodermic psoriasis are true emergencies requiring hospitalization, fluid and electrolyte management, and often cyclosporine or infliximab for rapid control — recognizing them quickly changes management from "outpatient cream" to "admit the patient."

Common Misunderstanding

Students often assume all psoriasis looks like thick, scaly plaques. Inverse and guttate psoriasis frequently lack heavy scale entirely, and pustular psoriasis can be mistaken for a bacterial skin infection even though the pustules are sterile.

Diagnosis and Differential

Diagnosis is primarily clinical, based on morphology and distribution, with biopsy reserved for atypical presentations.

• Physical examination: distribution, Auspitz sign (pinpoint bleeding on scale removal), Koebner phenomenon, nail findings (pitting, onycholysis, "oil drop" sign)
• Skin biopsy: shows parakeratosis, acanthosis with elongated rete ridges, thinned suprapapillary plates, and neutrophilic microabscesses (Munro microabscesses) in the stratum corneum
• Screening for comorbidity: joint exam for psoriatic arthritis, lipid panel and blood pressure given cardiovascular risk, mental health screening for depression/anxiety
• Differential diagnosis: seborrheic dermatitis (greasier scale, nasolabial folds), tinea corporis (KOH prep positive, annular with central clearing), lichen planus (violaceous, polygonal, pruritic papules — the six P's), atopic dermatitis (flexural, intensely pruritic, personal/family atopy history)

Treatment Ladder

Treatment intensity is matched to body surface area (BSA) involved and quality-of-life impact, not just BSA alone — a small plaque on the palm or genitals can justify systemic therapy because of its functional impact.

• Topical: corticosteroids (potency matched to site), vitamin D analogs, calcineurin inhibitors for flexural sites, tar and topical retinoids
• Phototherapy: narrowband UVB is first-line for moderate disease; PUVA (psoralen plus UVA) is more effective but carries higher long-term skin cancer risk
• Conventional systemics: methotrexate (folate antagonist, monitor LFTs and CBC), cyclosporine (fast-acting, used short-term due to nephrotoxicity), apremilast (PDE4 inhibitor, oral, milder side effect profile)
• Biologics: TNF-alpha inhibitors (etanercept, adalimumab, infliximab), IL-17 inhibitors (secukinumab, ixekizumab), IL-23 inhibitors (guselkumab, risankizumab), and the combined IL-12/23 inhibitor ustekinumab — all require screening for latent TB and hepatitis B before initiation

Complications and Comorbidities

Psoriasis is now recognized as a systemic inflammatory disease rather than a skin-limited condition.

• Psoriatic arthritis: develops in up to 30% of psoriasis patients, usually years after skin disease onset; presents with dactylitis ("sausage digits"), enthesitis, and asymmetric oligoarthritis; nail pitting strongly correlates with joint involvement
• Cardiovascular disease: chronic systemic inflammation accelerates atherosclerosis; severe psoriasis is an independent cardiovascular risk factor comparable to some traditional risk factors
• Metabolic syndrome: increased prevalence of obesity, diabetes, and dyslipidemia
• Psychiatric impact: depression and anxiety are common given the visible, chronic, relapsing nature of the disease
• Psoriatic nail disease: pitting, onycholysis, subungual hyperkeratosis, and the oil-drop sign

Key Terms

Term	Definition	Related Concept
Koebner phenomenon	New psoriatic lesions appearing at sites of skin trauma (scratches, cuts, sunburn)	Also seen in lichen planus and vitiligo
Auspitz sign	Pinpoint bleeding when psoriatic scale is scraped off, from thinned suprapapillary epidermis over dilated vessels	Distinguishes psoriasis from other scaly dermatoses
Parakeratosis	Retention of nuclei in the stratum corneum, indicating abnormally fast keratinocyte turnover	Histologic hallmark of psoriasis
Munro microabscess	Collection of neutrophils within the stratum corneum	Seen in psoriasis biopsy, distinguishes from eczema
Th17 cell	T-helper subset producing IL-17, central driver of psoriatic inflammation	IL-23/Th17 axis, target of biologics
Psoriatic arthritis (PsA)	Inflammatory arthritis occurring in psoriasis patients, often with dactylitis and enthesitis	Seronegative spondyloarthropathy
Dactylitis	Diffuse swelling of an entire finger or toe ("sausage digit")	Hallmark feature of psoriatic arthritis
Guttate psoriasis	Drop-shaped psoriasis lesions, often post-streptococcal	Molecular mimicry with keratin
Biologic	Targeted injectable/infused therapy against a specific cytokine (TNF, IL-17, IL-23)	Moderate-to-severe disease management
Erythroderma	Generalized erythema and scaling affecting most of the body surface	Dermatologic emergency

Common Mistakes

Misconception: Psoriasis is just dry skin or a cosmetic nuisance that can be managed with moisturizer alone. Why it's wrong: Psoriasis is a systemic, T-cell mediated inflammatory disease. Moisturizer does not address the underlying IL-23/Th17 cytokine drive, and untreated moderate-to-severe disease carries real risk of psoriatic arthritis and cardiovascular disease. Correct understanding: Treatment should be matched to disease severity and systemic risk, not just visible skin involvement. Even patients with modest BSA but joint symptoms or high-impact-site involvement may need systemic therapy.

Misconception: All psoriasis looks the same — thick, scaly, well-demarcated plaques. Why it's wrong: Inverse psoriasis in flexural folds is smooth and minimally scaly due to moisture; pustular psoriasis shows sterile pustules rather than scale; guttate psoriasis presents as small drop-like papules. Correct understanding: Recognize psoriasis by its underlying pattern (well-demarcated, symmetric, extensor-favoring in classic disease) while accounting for site-specific and subtype-specific variation in scale and morphology.

Misconception: Stopping oral or systemic corticosteroids abruptly in a psoriasis patient is a routine, safe way to taper treatment. Why it's wrong: Rapid corticosteroid withdrawal in psoriasis patients is a well-documented trigger for generalized pustular psoriasis (von Zumbusch type), a life-threatening emergency with risk of sepsis and hypovolemia. Correct understanding: Systemic corticosteroids are generally avoided in psoriasis management altogether; when used, they must be tapered cautiously with close dermatology involvement.

Comparison and Connections

Feature	Psoriasis	Seborrheic Dermatitis	Lichen Planus	Atopic Dermatitis (Eczema)
Scale character	Thick, silvery, well-demarcated	Greasy, yellowish scale	Fine, adherent "Wickham striae"	Excoriated, weepy, poorly demarcated
Distribution	Extensor surfaces, scalp, lumbosacral	Nasolabial folds, scalp, eyebrows	Wrists, ankles, oral mucosa	Flexural surfaces (antecubital, popliteal)
Pruritus	Variable, often mild-moderate	Mild	Intense	Intense, hallmark feature
Key sign	Auspitz sign, Koebner phenomenon	Not typically present	Six P's: Planar, Pruritic, Purple, Polygonal, Papules, Plaques	Family/personal atopy history
Pathogenesis	Th17-driven, IL-23 axis	Malassezia yeast overgrowth	T-cell mediated, drug/hepatitis C associations	IgE-mediated, filaggrin barrier defect

Practice Questions

Recall

1. What is the approximate keratinocyte turnover time in psoriatic skin compared to normal skin? Answer guidance: Normal turnover is about 28 days; in psoriasis it is accelerated to roughly 3–4 days.

2. Name the five major clinical subtypes of psoriasis. Answer guidance: Plaque (vulgaris), guttate, inverse (flexural), pustular, and erythrodermic.

Understanding

3. Why does removing psoriatic scale produce pinpoint bleeding (Auspitz sign)? Answer guidance: The suprapapillary epidermis is markedly thinned due to elongated rete ridges, sitting directly over dilated, tortuous dermal capillaries, so minor trauma to the scale exposes and ruptures these vessels.

4. Explain why biologic drug names map directly onto the IL-23/Th17 pathway. Answer guidance: Because the pathway itself is the therapeutic target — ustekinumab blocks the shared p40 subunit of IL-12/23, guselkumab and risankizumab block IL-23 specifically, and secukinumab/ixekizumab block IL-17, the effector cytokine driving keratinocyte hyperproliferation.

Application

5. A 30-year-old presents with new pink, scaly, drop-shaped papules on the trunk two weeks after a sore throat. What is the likely diagnosis and underlying mechanism? Answer guidance: Guttate psoriasis, likely triggered by streptococcal pharyngitis via molecular mimicry between streptococcal M-protein and keratin.

6. A patient with known psoriasis is tapered off a course of oral prednisone prescribed elsewhere for a separate condition and develops widespread pustules with fever. What happened and what is the priority? Answer guidance: Rapid corticosteroid withdrawal precipitated generalized pustular psoriasis (von Zumbusch). This is a dermatologic emergency requiring hospitalization, fluid/electrolyte management, and urgent dermatology involvement — not outpatient management.

Analysis

7. A patient with psoriasis develops new-onset asymmetric swelling of an entire toe and morning stiffness. How does this change the treatment approach compared to skin disease alone? Answer guidance: Dactylitis and morning stiffness suggest psoriatic arthritis, which shifts management toward systemic therapy (methotrexate or a biologic) that treats both joint and skin disease, since topical therapy alone does not address joint inflammation. This also affects choice of biologic — IL-17 and TNF inhibitors have strong joint-disease evidence.

8. Compare why inverse psoriasis is more frequently misdiagnosed than plaque psoriasis, and what clinical clues correct the error. Answer guidance: Inverse psoriasis lacks the thick scale expected from psoriasis because moisture in flexural folds keeps plaques thin, shiny, and macerated, resembling candidal intertrigo or tinea. Clues that correct the error include well-demarcated borders (fungal infections often have more irregular, advancing borders with satellite lesions), a negative KOH prep, and psoriasis elsewhere on extensor surfaces or nails.

FAQ

Q: Is psoriasis contagious? No. Psoriasis is an immune-mediated disease, not an infection, and cannot be transmitted by skin contact. This is a common patient concern worth addressing directly, since visible plaques often lead to social stigma.

Q: Can psoriasis be cured? There is currently no cure, but biologic therapy can achieve near-complete skin clearance (PASI 90–100) in many patients with moderate-to-severe disease. Psoriasis is managed as a chronic relapsing-remitting condition, similar to how asthma or diabetes is controlled rather than cured.

Q: Why do doctors ask about joint pain in a patient with a skin rash? Because up to 30% of psoriasis patients eventually develop psoriatic arthritis, often years after skin onset. Early features like dactylitis, enthesitis (heel pain from Achilles tendon inflammation), and morning stiffness can be easy to miss if the clinician is only looking at the skin.

Q: Why does a strep throat infection trigger a skin rash? This is guttate psoriasis, thought to arise from molecular mimicry — streptococcal M-protein resembles keratin closely enough that the antistreptococcal immune response cross-reacts with skin, triggering the same Th17-driven cascade seen in classic psoriasis.

Q: Why are biologics so expensive and are they really necessary? Biologics are large, complex proteins that are costly to manufacture, but for patients with moderate-to-severe disease unresponsive to topical and phototherapy, they offer dramatically better clearance rates and quality of life than older systemic drugs, with a more favorable long-term safety profile than continuous methotrexate or cyclosporine. Necessity is judged by BSA, functional impact, and presence of psoriatic arthritis, not cosmetic preference alone.

Quick Revision

• Psoriasis is a T-cell mediated (Th17/IL-23 axis) inflammatory disease, not primarily a keratinocyte disorder
• Normal keratinocyte turnover is ~28 days; in psoriasis it is accelerated to ~3–4 days
• Five subtypes: plaque (most common), guttate (post-strep, children), inverse (flexural, minimal scale), pustular (can be an emergency), erythrodermic (always an emergency)
• Koebner phenomenon: new lesions at sites of skin trauma
• Auspitz sign: pinpoint bleeding when scale is removed, due to thinned suprapapillary epidermis over dilated vessels
• Histology: parakeratosis, acanthosis, elongated rete ridges, Munro microabscesses
• Up to 30% of psoriasis patients develop psoriatic arthritis — screen for dactylitis, enthesitis, nail pitting
• Psoriasis carries increased cardiovascular and metabolic disease risk from chronic systemic inflammation
• Treatment ladder: topicals → phototherapy (narrowband UVB) → conventional systemics (methotrexate, cyclosporine, apremilast) → biologics
• Biologic classes: anti-TNF, anti-IL-17, anti-IL-23, anti-IL-12/23 (ustekinumab)
• Rapid corticosteroid withdrawal can trigger generalized pustular psoriasis — avoid systemic steroids in psoriasis
• Screen for latent TB and hepatitis B before starting biologics

Related Topics

Prerequisites: Skin structure and keratinocyte biology (see Introduction to Dermatology), basic immunology (T-cell subsets, cytokine signaling), inflammation basics

Related Topics: Rheumatology (seronegative spondyloarthropathies, psoriatic arthritis), Pharmacology (biologic agents, immunosuppressants, TB/hepatitis screening), Eczema and Dermatitis (differential diagnosis)

Next Topics: Psoriatic Arthritis and Spondyloarthropathies, Biologic Therapies in Dermatology, Skin Infections and Infestations